Reddys Laboratories Ltd announced today that it has launched Raloxifene hydrochloride
tablets in 60 mg, a therapeutic equivalent generic version of Evista (raloxifene hydrochloride
) tablets in the United States market, approved by the U.
Pharmaceutical company Dr Reddy's Laboratories (NSE:DRREDDY)(NYSE:RDY) reported on Friday the availability of Raloxifene hydrochloride
tablets in 60 mg in the US market.
The company has been granted clearance for raloxifene hydrochloride
tablets USP, 60 mg, the therapeutic equivalent to Evista Tablets (Eli Lilly & Co.
, a pale yellow solid which is slightly soluble in water [4,5].
60 mg/day was administered for 6 months.
Background Raloxifene hydrochloride
is a selective estrogen receptor modulator that inhibits bone resorption without stimulating the breast or the uterine endometrium.
Evista, the brand name for raloxifene hydrochloride
, is the first of a new class of drugs approved for the prevention of osteoporosis.
, sold under the brand name Evista, was designed to prevent brittle bone disease in older women.
Based on this ruling, the Court enjoined Teva from commencing the commercial launch of generic raloxifene hydrochloride
tablets prior to the expiration date of those patents.
6 May 2010 - US Watson Pharmaceuticals Inc (NYSE: WPI) said yesterday that its subsidiary, Watson Laboratories Inc, filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market a raloxifene hydrochloride
The drug raloxifene hydrochloride
, sold under the brand name Evista, is designed to prevent brittle bone disease in postmenopausal women.